Abstract: Provided herein are methods to determine the safety of quercetin compositions regarding contaminants that can result from the degradation of quercetin, such as by storage of solid form quercetin compositions in an air atmosphere. The contaminants include protocatechuic acid, 2,4,6-trihydroxybenzoic acid, and 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid. Provided herein are also methods which reduce degradation of solid form quercetin compositions and reduce the formation of such toxic compounds. The provided methods increase the shelf life and patient safety of quercetin compositions.

Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.

Abstract: Provided herein are methods to determine the safety of quercetin compositions regarding contaminants that can result from the degradation of quercetin, such as by storage of solid form quercetin compositions in an air atmosphere. The contaminants include protocatechuic acid, 2,4,6-trihydroxybenzoic acid, and 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid. Provided herein are also methods which reduce degradation of solid form quercetin compositions and reduce the formation of such toxic compounds. The provided methods increase the shelf life and patient safety of quercetin compositions.

Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.

Abstract: Novel p62/SQSTM1 compositions for the prophylaxis and treatment of agerelated macular degeneration. Modified p62 compositions and methods to increase activity of p62 for such prophylaxis and treatment.

Abstract: The present invention relates generally to methods for introducing mutations that alter the probability of intranucleic acid base pairing of a conserved structured nucleotide in a nucleic acid. The present invention also provide methods for making mutant pathogenic organisms suitable as live attenuated vaccines, animal and human diagnostics, and for identifying suitable drug targets.

Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.

Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.

Abstract: Provided herein are compositions and methods which reduce degradation of solid form quercetin compositions and reduce the formation of a toxic compound, 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid. Also provided are containers and kits that contain solid form quercetin compositions with reduced degradation of quercetin and reduced formation of 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid. The provided composition and methods increase the shelf life and patient safety of solid form quercetin compositions.

Abstract: Provided herein are compositions and methods which reduce degradation of solid form quercetin compositions and reduce the formation of a toxic compound, 2,4,6-trihydroxybenzoic acid (2,4,6-THBA). Also provided are containers and kits that contain solid form quercetin compositions with reduced degradation of quercetin and reduced formation of 2,4,6-THBA. The provided composition and methods increase the shelf life and patient safety of solid form quercetin compositions.

Abstract: Provided herein are methods to determine the safety of quercetin compositions regarding contaminants that can result from the degradation of quercetin, such as by storage of solid form quercetin compositions in an air atmosphere. The contaminants include protocatechuic acid, 2,4,6-trihydroxybenzoic acid, and 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid. Provided herein are also methods which reduce degradation of solid form quercetin compositions and reduce the formation of such toxic compounds. The provided methods increase the shelf life and patient safety of quercetin compositions.

Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.

Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.

Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.

Abstract: The present invention relates generally to methods for introducing mutations that alter the probability of intranucleic acid base pairing of a conserved structured nucleotide in a nucleic acid. The present invention also provide methods for making mutant pathogenic organisms suitable as live attenuated vaccines, animal and human diagnostics, and for identifying suitable drug targets.

Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.

Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.

Abstract: The number of citations in scientific papers referencing an individual scientist plays a key role in their professional life and in scientific communities. Today's exponentially growing number of scientific publications makes it nearly impossible for authors to reflect all papers that may deserve citations. Often, authors learn about a paper they would have cited only after their work is published, and the situation cannot be corrected. We have invented a method which allows authors to appropriately reference the work of others by enabling the addition of citations to papers which have already been published. This method is implemented via the Internet system and contains one or more of the following elements: Post-Publication Citation List, Citations Under Discussion List, Non-Citators List, and a system enabling dialog between parties.

Abstract: Compositions of anti-influenza vaccine containing nucleic acids encoding influenza proteins NP, M1 and NS-1 and methods of inducing a protective immune response using these compositions. Also included is the enhancement of antigenic presentation or increasing immunogenicity of an influenza NP, M1 and/or NS-1 polypeptide by modifying the three dimensional structure of the polypeptide.

Abstract: Compositions of anti-influenza vaccine containing nucleic acids encoding influenza proteins NP, M1 and NS-1 and methods of inducing an immune response using these compositions. Also included is the enhancement of antigenic presentation or increasing immunogenicity of an influenza NP, M1 and/or NS-1 polypeptide by modifying the three dimensional structure of the polypeptide.